We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Noninvasive Neurostimulator Helps Prevent Cluster Headaches

By HospiMedica International staff writers
Posted on 12 Dec 2018
A novel non-invasive vagus nerve stimulation (nVNS) device excites the nerve’s afferent fibers, leading to headache pain reduction.

The electroCore (Basking Ridge, NJ, USA) gammaCore is hand-held adjunctive therapy device indicated for the prevention of cluster headaches and for the treatment of the acute pain associated with episodic cluster headache and migraine. More...
The portable device provides a mild electrical stimulation to the vagus nerve, without the potential side effects associated with commonly prescribed drugs. The self-administered treatment consists of three consecutive two-minute stimulations twice a day, with the first treatment applied within one hour of waking up and the second seven to 10 hours later; the device does not prevent migraines.

In two clinical studies, nVNS patients had 3.9 fewer cluster attacks per week than those who received standard of care (SOC). In addition, 40% of those patients who received gammaCore in addition to SOC experienced a 50% or greater reduction in weekly cluster attacks, compared to 8.3% of patients who received SOC alone. Also, a 57% decrease in the frequency of abortive medication use among those who received gammaCore plus SOC care was demonstrated, while those patients who received SOC alone did not experience a substantial reduction.

“Clearance of gammaCore for adjunctive use for the preventive treatment of cluster headache has the potential to help the approximately 350,000 Americans impacted by this debilitating condition, often referred to as a suicide headache,” said Frank Amato, CEO of electroCore. “We are pleased that cluster headache patients now have a FDA-cleared option, and one that is both safe and effective, especially given the difficulty in treating cluster headache and the limitations of current treatments.”

Cluster headache is a rare but extremely painful disorder characterized by recurring unilateral attacks. The condition is the least common type of headache disorder, occurring in 1-2 out of 1,000 individuals, affecting predominantly males, heavy smokers and those with a family history. Symptoms typically manifest by age 30. Frequently nicknamed “suicide headache” due to the severity of pain associated with their occurrence, cluster headache bouts occur rapidly and with variable frequency, but often at the same time each year or day and are often more frequent at night.

Related Links:
electroCore


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.